{"entity":{"id":"capstan-therapeutics","kind":"company","name":"Capstan Therapeutics","aka":[],"tldr":"Capstan built a way to create CAR T cells inside the patient's body by delivering messenger RNA in targeted lipid nanoparticles, avoiding the need to manufacture cells outside the body. AbbVie bought it in 2025 for $2.1 billion.","summary":"Capstan Therapeutics developed in vivo CAR T therapy using targeted lipid nanoparticles (tLNP) that deliver RNA payloads such as mRNA to specific immune cells so that CAR T cells are generated inside the patient. Its lead candidate CPTX2309 (now ABBV-619) is an anti-CD19 in vivo CAR T in phase 1 for B cell-mediated autoimmune diseases; the platform is also applicable to oncology. SEC Form D filings show the company was incorporated in 2020 and sold roughly $63 million (2021), $76 million (2022) and $87 million of a $175 million offering (2024) in equity. AbbVie completed its acquisition of Capstan in August 2025 for cash consideration of $2.1 billion, accounted for as an asset acquisition, as disclosed in AbbVie's third-quarter 2025 Form 10-Q.","asOf":"2026-09-10","links":[{"label":"Official website","url":"https://www.sec.gov/edgar/browse/?CIK=0002015437"},{"label":"AbbVie Q3 2025 Form 10-Q describing the acquisition","url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/abbv-20250930.htm"},{"label":"AbbVie Q3 2025 results noting completion (8-K)","url":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000047/abbv-20250930xexhibit991.htm"},{"label":"SEC EDGAR filings","url":"https://www.sec.gov/edgar/browse/?CIK=0002015437"}],"tags":[],"related":[],"cancers":[],"sections":["cell-therapy"],"technologies":["in-vivo-car-t"],"targets":["cd19"],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["capstantx.com redirects to an AbbVie page that returned HTTP 403 to automated fetches, so the EDGAR page is given as website. Lead indication is autoimmune rather than cancer; the Form D filings do not name series letters. Investor names not sourced."],"hq":"San Diego, CA","country":"US","companyType":"cell-therapy","founded":2020,"stage":"acquired","investors":[],"funding":[{"round":"Form D offering","year":2021,"amountUsd":62999992,"source":"https://www.sec.gov/Archives/edgar/data/2015437/000201543724000001/primary_doc.xml","note":"Equity offering, first sale 24 November 2021 (filed March 2024)"},{"round":"Form D offering","year":2022,"amountUsd":76499983,"source":"https://www.sec.gov/Archives/edgar/data/2015437/000201543724000002/primary_doc.xml","note":"Amount sold of a $102 million offering, first sale 14 June 2022 (filed March 2024)"},{"round":"Form D offering","year":2024,"amountUsd":87499982,"source":"https://www.sec.gov/Archives/edgar/data/2015437/000201543724000003/primary_doc.xml","note":"Amount sold at filing of a $175 million offering, first sale 5 March 2024"},{"round":"Acquisition","year":2025,"amountUsd":2100000000,"source":"https://www.sec.gov/Archives/edgar/data/1551152/000155115225000049/abbv-20250930.htm","note":"AbbVie paid cash consideration of $2.1 billion ($1.9 billion net of cash acquired); completed August 2025"}],"acquiredBy":"abbvie"},"route":"/companies/capstan-therapeutics/","neighbours":{"section":[{"id":"cell-therapy","kind":"section","name":"Cell Therapy","route":"/fronts/cell-therapy/"}],"technology":[{"id":"in-vivo-car-t","kind":"technology","name":"In vivo CAR-T","route":"/technologies/in-vivo-car-t/"}],"target":[{"id":"cd19","kind":"target","name":"CD19","route":"/targets/cd19/"}],"company":[{"id":"abbvie","kind":"company","name":"AbbVie (incl. ImmunoGen, Capstan)","route":"/companies/abbvie/"}]}}